/oss/taxonomy/term/7233/all en /oss/article/medical-contributors/we-know-about-type-1-and-type-2-diabetes-what-type-3-diabetes <p>The incidence of diabetes mellitus has reached epidemic levels in recent years, affecting one in every 10 adults globally in 2021. Ninety percent of these individuals have Type 2 Diabetes (T2D) which is characterized by two defects, namely resistance to the metabolic actions of insulin in combination with an inability of the pancreatic islet beta-cells to secrete enough insulin to overcome this resistance. T2D is also often associated with overweight or obesity, which plays a role in the development of the insulin resistance.</p> Fri, 12 Apr 2024 13:25:03 +0000 Patricia Brubaker, Ph.D., F.R.S.C. 9907 at /oss /oss/article/medical-health-and-nutrition/what-next-evolution-glp-1-based-therapies-diabetes-and-obesity <p>The first glucagon-like peptide-1 (GLP-1)-based therapeutic was approved by Health Canada in 2011 for the treatment of hyperglycemia in patients with Type 2 diabetes. Little was it suspected at that time that this class of drugs would go on to become a global success not only for Type 2 diabetes but, now, also for people living with overweight/obesity. Since that time, numerous variants of GLP-1 have been developed, with at least 7 different forms in trials or available today.</p> Fri, 15 Dec 2023 20:17:14 +0000 Patricia Brubaker, Ph.D., F.R.S.C. 9763 at /oss /oss/article/medical/type-2-diabetes-what-why-and-how <p>November is National Diabetes Awareness Month. It therefore timely to consider what diabetes actually is, why we should care, and how it can be treated. Diabetes, or more technically, diabetes mellitus, now affects 10% of Canadians, with the numbers increasing annually, not only in Canada but worldwide.</p> Fri, 17 Nov 2023 15:22:11 +0000 Patricia Brubaker, Ph.D., F.R.S.C. 9730 at /oss